Insider Selling: Prestige Consumer Healthcare Inc. (NYSE:PBH) CEO Sells 10,875 Shares of Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Prestige Consumer Healthcare Trading Up 0.8 %

NYSE PBH opened at $84.85 on Friday. Prestige Consumer Healthcare Inc. has a 52 week low of $56.61 and a 52 week high of $85.22. The business has a 50 day moving average price of $74.34 and a 200-day moving average price of $70.68. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The company has a market cap of $4.19 billion, a price-to-earnings ratio of 20.64, a P/E/G ratio of 2.37 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business’s revenue was down .9% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.07 earnings per share. As a group, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson reaffirmed a “buy” rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several large investors have recently added to or reduced their stakes in the business. Opal Wealth Advisors LLC bought a new stake in Prestige Consumer Healthcare during the 2nd quarter worth approximately $26,000. Quest Partners LLC grew its holdings in Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after buying an additional 424 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after buying an additional 208 shares in the last quarter. Gladius Capital Management LP bought a new position in Prestige Consumer Healthcare during the 2nd quarter valued at $35,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after acquiring an additional 433 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.